About ADMPFounded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty biopharmaceutical company that provides high quality, low-cost solutions for patients, physicians, and healthcare organizations in the multi-billion dollar therapeutic areas of respiratory disease and allergies. The Company’s lead pipeline product is an epinephrine injection pre-filled syringe product for potential use in the emergency treatment of anaphylaxis. Adamis is also currently developing other specialty pharmaceutical product candidates including APC-1000 and APC-5000 for the potential treatment of asthma and chronic obstructive pulmonary disease, APC-2000 for the treatment of bronchospasms, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. With the rising costs of healthcare in recent years, Adamis has been focusing on creating low-cost therapeutic alternatives in large markets in order to grow its business and to make treatments more affordable for more people. Adamis will pursue the 505(b)(2) regulatory approval filing with the FDA whenever possible in order to minimize costs and shorten the time to market.
|ETF Ticker||ETF Name||Net Assets||Net Assets Raw||# Holdings||# Holdings Raw||Weight||Weight Raw||Market Value||Market Value Raw|
|Vanguard Total Stock Market ETF||119.5 B||1.195E+11||3,575||3575||0.0%||0||172 K||172484|
|Vanguard Extended Market ETF||7.3 B||7.3E+09||3,266||3266||0.0%||1E-05||69 K||69068|
|iShares Core S&P Total U.S. Stock Market ETF||22.0 B||2.20343E+10||3,546||3546||0.0%||0||8 K||7998|
|iShares Microcap ETF||800.2 M||8.00224E+08||1,388||1388||0.02%||0.0002||127 K||127421|